NASDAQ$ACLX
Arcellx Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Arcellx reported financial results and business progress for Q3 2022.
Arcellx reported a net loss of $92.9 million for the third quarter ended September 30, 2022. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months.
- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA.
- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in December.
- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022.
- Began to operationally scale by initiating clinical sites, enrolling patients and dosing our first patients from Lonza, our pivotal cell manufacturer.
Headline financials
Revenue & EPS history
Arcellx · Revenue · Quarterly
$0
Forward guidance
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
+2.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+24.9%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+16.0%
Q2 2024
Best reaction
-4.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.2% | -0.1% | +0.2% | |
| Q3 2025 | -1.9% | +2.2% | -21.1% | |
| Q2 2025 | -0.9% | -0.2% | +2.1% | |
| Q1 2025 | -0.2% | +10.9% | +9.0% | |
| Q4 2024 | +2.0% | +1.2% | -19.9% | |
| Q3 2024 | +10.8% | +8.1% | -9.1% | |
| Q2 2024 | +16.0% | +19.1% | +40.0% | |
| Q1 2024 | -4.8% | -3.1% | -2.8% | |
| Q4 2023 | -2.7% | +0.4% | +2.9% | |
| Q3 2023 | +4.3% | +21.3% | +11.0% | |
| Q2 2023 | +6.7% | +3.3% | -0.7% | |
| Q1 2023 | +2.8% | -4.5% | -3.7% | |
| Q4 2022 | +0.9% | -2.9% | +41.1% | |
| Q3 2022 | -2.8% | -4.9% | +47.5% | |
| Q3 2021 | -2.8% | -4.9% | +47.5% | |
| Q2 2022 | +8.4% | -4.1% | +10.5% | |
| Q1 2022 | +0.2% | -15.5% | +174.8% | |
| Q1 2021 | +0.2% | -15.5% | +174.8% | |
| Q4 2021 | +5.9% | -8.7% | -30.2% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro